Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J’s Stelara Beats Enbrel In Psoriasis

This article was originally published in The Pink Sheet Daily

Executive Summary

New survey shows doctors are warming to another rival, Humira.

You may also be interested in...



Amgen Taps GSK's Stiefel Unit To Promote Enbrel To Dermatologists

Deal will aid Amgen's promotional efforts around Enbrel in psoriasis as the entrenched biologic faces down Humira, Stelara in the market.

Amgen Taps GSK's Stiefel Unit To Promote Enbrel To Dermatologists

Deal will aid Amgen's promotional efforts around Enbrel in psoriasis as the entrenched biologic faces down Humira, Stelara in the market.

Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers

Centocor Ortho Biotech's Stelara (ustekinumab) brings a novel mechanism and superior efficacy to the plaque psoriasis marketplace, but in terms of risk management, the anti-inflammatory biologic differs little from the tumor necrosis factor inhibitor class

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068365

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel